Biotech RadarJobs updated

COMPANY

Atea Pharmaceuticals

HQ: Boston, MA source · ateapharma.com ↗ · New England

Clinical Phase 3

Keywords: infectious disease viral infections hepatitis C hepatitis E Chronic Hepatitis C Hepatitis C Virus Infection Hepatic Impairment Renal Impairment HEPATITIS C VIRUS CHRONIC INFECTION COVID-19 Dengue HCV Infection Chronic Hepatitis C Virus Hepatic Cirrhosis HCV Dengue Fever Bemnifosbuvir AT-527 AT-752 Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination AT-587 AT-777 AT-527 (R07496998)

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

33Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Study of AT-587 in Healthy Subjects source ↗
  2. Trial start Phase 1: Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) source ↗
  3. Trial start Phase 3: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV source ↗
  4. Trial start Phase 1: Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir source ↗
  5. Trial start Phase 1: Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function source ↗
  6. Trial start Phase 1: Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin source ↗
  7. Trial start Phase 3: C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV source ↗
  8. Trial start Phase 1: Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone source ↗
  9. Trial start Phase 1: Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir source ↗
  10. Trial start Phase 1: Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir source ↗
  11. Trial start 2: A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV source ↗
  12. Trial start Phase 1: The Study of Bemnifosbuvir in Healthy Japanese Subjects source ↗
  13. Trial start Phase 1: Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects source ↗
  14. Trial start Phase 1: Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function source ↗
  15. Trial start Phase 1: Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir source ↗
  16. Trial start Phase 3: SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 source ↗
  17. Trial start Phase 1: Study of AT-527 in Subjects With Normal and Impaired Renal Function source ↗
  18. Trial start Phase 2: Study of AT-752 in Patients With Dengue Infection source ↗
  19. Trial start Phase 1: Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model source ↗
  20. Trial start Phase 1: Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal source ↗
  21. Trial start Phase 1: Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) source ↗
  22. Trial start Phase 1: Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) source ↗
  23. Trial start Phase 1/Phase 2: Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects source ↗
  24. Trial start Phase 1: Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) source ↗
  25. Trial start Phase 1: Bronchopulmonary PK of AT-527 (R07496998) source ↗

Showing 25 of 33 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 33

RecordTitlePhaseStatusStartPrimary completion
NCT06911320Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionPhase 1CompletedApr 9, 2025Apr 30, 2026 (actual)
NCT07728487Study of AT-587 in Healthy SubjectsPhase 1RecruitingJul 13, 20262026-12 (estimated)
NCT07314346Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or MethadonePhase 1RecruitingJan 7, 20252026-08 (estimated)
NCT07037277C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVPhase 3Active, not recruitingJun 2, 20252026-12 (estimated)
NCT07272889Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)Phase 1CompletedDec 4, 2025Feb 17, 2026 (actual)
NCT06868264C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVPhase 3Active, not recruitingApr 7, 20252026-09 (estimated)
NCT05904470A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV2CompletedMay 30, 2023Dec 9, 2024 (actual)
NCT07007806Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/RuzasvirPhase 1CompletedMay 9, 2025Jun 28, 2025 (actual)
NCT06921941Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinPhase 1CompletedApr 8, 2025Jul 2, 2025 (actual)
NCT05629962SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19Phase 3CompletedNov 25, 2022Apr 25, 2024 (actual)
NCT06204679Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and RuzasvirPhase 1CompletedDec 14, 2023Aug 25, 2024 (actual)
NCT06356194Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/RuzasvirPhase 1CompletedApr 15, 2024May 30, 2024 (actual)
NCT05618314Study of AT-527 in Subjects With Normal and Impaired Renal FunctionPhase 1CompletedOct 17, 2022Jun 15, 2024 (actual)
NCT05724693Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic FunctionPhase 1CompletedJan 30, 2023Apr 23, 2024 (actual)
NCT05466240Study of AT-752 in Patients With Dengue InfectionPhase 2TerminatedApr 29, 2022Jan 19, 2023 (actual)
NCT05905484Study of Bemnifosbuvir on Cardiac Repolarization in Healthy SubjectsPhase 1CompletedApr 25, 2023May 31, 2023 (actual)
NCT05905497The Study of Bemnifosbuvir in Healthy Japanese SubjectsPhase 1CompletedApr 26, 2023May 19, 2023 (actual)
NCT05731843Drug-drug Interaction Study of Ruzasvir and BemnifosbuvirPhase 1CompletedJan 30, 2023Mar 15, 2023 (actual)
NCT05366439Study of AT-752 in Healthy Subjects in a Dengue Human Challenge ModelPhase 1TerminatedApr 22, 2022Mar 16, 2023 (actual)
NCT04396106Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital SettingPhase 2TerminatedMay 26, 2020Jan 10, 2022 (actual)
NCT05256732Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a MealPhase 1CompletedFeb 22, 2022Aug 23, 2022 (actual)
NCT04722627Study of AT-752 in Healthy SubjectsPhase 1CompletedMar 9, 2021Nov 14, 2021 (actual)
NCT04309734Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected SubjectsPhase 1/Phase 2Withdrawn2021-102022-06 (estimated)
NCT05137626Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)Phase 1CompletedNov 3, 2021Dec 12, 2021 (actual)
NCT05154123Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)Phase 1CompletedNov 16, 2021Dec 23, 2021 (actual)
NCT04711187Study of AT-527 in Healthy Subjects (R07496998)Phase 1CompletedNov 2, 2020Sep 15, 2021 (actual)
NCT04877769Bronchopulmonary PK of AT-527 (R07496998)Phase 1CompletedApr 25, 2021Aug 31, 2021 (actual)
NCT05004415Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)Phase 1CompletedJul 28, 2021Aug 12, 2021 (actual)
NCT04849299Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)Phase 1CompletedApr 18, 2021May 10, 2021 (actual)
NCT04784000Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527Phase 1CompletedMar 1, 2021Apr 10, 2021 (actual)
NCT04865445Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)Phase 1CompletedApr 22, 2021May 15, 2021 (actual)
NCT04019717Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) InfectionPhase 2CompletedJun 20, 2019Jan 29, 2020 (actual)
NCT03219957Study of AT-527 in Healthy and HCV-Infected SubjectsPhase 1CompletedJul 6, 2017Jun 20, 2018 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback